Regulus Therapeutics Inc. (RGLS) News Nov 20, 2014, 5:14

New Post Public Reply Private Reply Replies (0) Message Board

Nov 21, 2014 at 5:21 AM

Regulus Therapeutics Inc. (RGLS) News Nov 20, 2014, 5:14 p.m.
MarketWatch News on RGLS
6 stocks to watch 3:06 p.m. Nov. 5, 2014 - The Trading Deck
Berkshire investment boost, new CFO give a lift to DaVita shares 10:17 a.m. July 8, 2013 - Russ Britt
Intercept Pharma, Kythera take off in IPOs 10:53 a.m. Oct. 11, 2012 - MarketWatch.com
Intercept Pharma, Kythera take off in IPOs 10:34 a.m. Oct. 11, 2012 - MarketWatch.com
Thursday’s biggest gaining and declining stocks 3:24 p.m. Oct. 4, 2012 - MarketWatch

Other News on RGLS
Regulus To See Further Declines 10:30 a.m. Nov. 19, 2014 - Seeking Alpha
Strong On High Relative Volume: Regulus Therapeutics (RGLS) 10:01 a.m. Nov. 18, 2014 - TheStreet.com
Regulus Therapeutics' (RGLS) CEO Kleanthis Xanthopoulos Presents at Credit Suisse 2014 Healthcare Conference (Transcript) 8:15 p.m. Nov. 12, 2014 - Seeking Alpha
Gilead presents Harvoni data 11:03 a.m. Nov. 11, 2014 - Seeking Alpha
AbbVie presents HCV/HIV and liver transplant HCV data 10:07 a.m. Nov. 11, 2014 - Seeking Alpha
Merck presents data from its investigational HCV combo 9:37 a.m. Nov. 11, 2014 - Seeking Alpha
Gilead presents data from three HCV drug combo studies 9:05 a.m. Nov. 11, 2014 - Seeking Alpha
Regulus Slumps: RGLS Falls 5.3% in Session - Tale of the Tape 8:53 a.m. Nov. 11, 2014 - Zacks.com
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting 10:40 a.m. Nov. 10, 2014 - TheStreet.com
Regulus Therapeutics (RGLS) Strong On High Relative Volume Today 10:04 a.m. Nov. 10, 2014 - TheStreet.com
Merck triple therapy HCV candidate fails as a four-week regimen 7:49 a.m. Nov. 10, 2014 - Seeking Alpha
Bristol-Myers presents data on HCV Trio regimen 6:04 p.m. Nov. 9, 2014 - Seeking Alpha
Bristol-Myers presents data on shorter regimen HCV drug combo 5:37 p.m. Nov. 9, 2014 - Seeking Alpha
Achillion presents HCV data at The Liver Meeting 5:06 p.m. Nov. 9, 2014 - Seeking Alpha
Trade-Ideas: Regulus Therapeutics (RGLS) Is Today's Post-Market Leader Stock 5:13 p.m. Nov. 7, 2014 - TheStreet.com
Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders 11:45 a.m. Nov. 6, 2014 - TheStreet.com
Regulus Therapeutics (RGLS) is in Overbought Territory: What's Next? - Tale of the Tape 9:12 a.m. Nov. 6, 2014 - Zacks.com
10-Q: REGULUS THERAPEUTICS INC. 6:10 a.m. Nov. 6, 2014 - Edgar Online - (EDG = 10Q, 10K)
Regulus Therapeutic's (RGLS) CEO Kleanthis Xanthopoulos on Q3 2014 Results -- Earnings Call Transcript 9:18 p.m. Nov. 5, 2014 - Seeking Alpha
Regulus Therapeutics (RGLS) Q3 2014 Results - Earnings Call Webcast 4:55 p.m. Nov. 5, 2014 - Seeking Alpha

Press Releases on RGLS
Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma, ZIOPHARM Oncology, Arena Pharma, and Regulus Therapeutics 8:40 a.m. Nov. 19, 2014 - PR Newswire - PRF
DexCom Announces Appointment of Mark G. Foletta as Board Member 8:31 a.m. Nov. 19, 2014 - BusinessWire - BZX
Critical Alerts For Zillow, Organovo, Regulus Therapeutics, JC Penney and FireEye Released By InvestorsObserver 9:31 a.m. Nov. 17, 2014 - PR Newswire - PRF
Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting 6:00 p.m. Nov. 15, 2014 - PR Newswire - PRF
Regulus to Present at the Credit Suisse Healthcare Conference 4:05 p.m. Nov. 6, 2014 - PR Newswire - PRF
Regulus Reports Third Quarter 2014 Financial Results and Recent Highlights 4:05 p.m. Nov. 5, 2014 - PR Newswire - PRF
Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 4:05 p.m. Nov. 3, 2014 - PR Newswire - PRF
Regulus Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call 3:05 p.m. Oct. 30, 2014 - PR Newswire - PRF
Regulus Announces Pricing of Public Offering of Common Stock 7:10 p.m. Oct. 28, 2014 - PR Newswire - PRF
Financial Results, Dividends, Positive Study Results, and Upcoming Earnings Releases - Research Reports on Varian Medical, Regulus, Cummins, AEP and NextEra 7:45 a.m. Oct. 28, 2014 - PR Newswire - PRF
Regulus Announces Commencement of Public Offering of Common Stock 3:00 p.m. Oct. 27, 2014 - PR Newswire - PRF
Critical Alerts For Apple, Regulus Therapeutics, iRobot, Nike and Twitter Released By InvestorsObserver 8:31 a.m. Oct. 23, 2014 - PR Newswire - PRF
Reveal Insider Trading for Yahoo, 3D Systems, Regulus Therapeutics, Huntington Bancshares, Cree, and AMD 7:45 a.m. Oct. 23, 2014 - PR Newswire - PRF
A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment History 6:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Regulus Presents New Preclinical Data on Multiple Programs and Provides Portfolio Overview at 10th Annual Oligonucleotide Therapeutics Society (OTS) Meeting 7:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
Regulus Announces Notice of Allowance from U.S. Patent Office Related to microRNA-103/107 Program in Metabolic Disorders 7:00 a.m. Sept. 24, 2014 - PR Newswire - PRF
Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 7:00 a.m. Sept. 18, 2014 - PR Newswire - PRF
Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024 12:22 p.m. Aug. 19, 2014 - PR Newswire - PRF
Regulus to Present at the Wedbush Life Sciences Management Access Conference 3:05 p.m. Aug. 7, 2014 - PR Newswire - PRF
Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis 7:00 a.m. Aug. 5, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AppLovin Faces Securities Fraud Lawsuit Amid AI Claims

Digging Into AppLovin's Legal Turmoil Well, it's another wrinkle in the markets' many lines. This time, we’ve got AppLovin Corporation facing the music with a securities fraud lawsuit. If you’ve got shares in NASDAQ:APP, you might want to perk up. Let the trial by fire begin, I say. The Lawsuit Details & Class Period Here we are, October 19, 2026, and the legal eagles...

Plata Hits $1 Billion ARR in Record Digital Bank Growth

Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...

Understanding Truck Accident Settlements in Memphis

Delving into Truck Accident Settlement Timelines Out there in Memphis, timing a truck accident settlement isn't exactly like clockwork work. When it comes to getting your compensation, the timeline varies as widely as a duck hunting trip—sometimes you come home with a basketful, sometimes it’s empty. It might be a quick couple of months or drag on past a year, and...

Navigating the Nitty-Gritty of Cabin Rental Management

The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

Tenant Improvement: Key to Adapting Lease Spaces

Adapting Space or Adapting Business? Here's the thing that keeps popping up in commercial real estate: tenant improvement construction. This isn't just modifying a structure—it's about rethinking how businesses operate within a certain space. The HelloNation article gives you the lowdown straight from Bradley Quakenbush of White Oak Commercial Group. When businesses...

De¹ Unveils Tokenization Model on BNB Chain

De¹'s Bold Move into Enhanced Digital Finance Just when you thought the financial landscape couldn’t get any more complex, De¹ steps into the ring with its Tokenized Asset World on the BNB Chain—a move that's stirring the pot of tokenized finance in more ways than one. For old-school investors who thrive on waving outlandish stock bets, this crypto narrative is a...

PrePass Intelligence: A Game-Changer for Fleets

Picture this: you're at the wheel of a beastly 18-wheeler, barreling down the highway and skipping weigh stations thanks to PrePass. But here’s where the real magic kicks in. PrePass Intelligence just rolled out, aiming to squeeze every last drop of value from bypass and toll data. That's cold hard cash for fleet operators who can finally make sense of these fleeting...

New Jersey Homeowners Face Mold Risks in Crawl Spaces

Understanding the Invisible Threat of Crawl Space Mold Crawl space mold—it hides in the shadows beneath your home, biding its time until it wreaks havoc on indoor air quality. In the context of New Jersey's environmental quirks, this isn't a trivial concern. With humidity hanging around like an unwanted guest and sneaky water intrusions, those dark nooks under houses...

Coastal Financial Faces Lawsuit Over Fraud Allegations

Coastal Financial Corporation, riding high on NASDAQ as CCB, now finds itself in the middle of a storm. Schall, Brown & Schwartz LLP, a firm known for its shareholder rights litigation, has thrown the gauntlet with a class action lawsuit against Coastal for suspected securities violations. We're talking about potential fibs under Section 10(b) and 20(a) of the Securities...